PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jathtrainLink to Publisher's site
 
J Athl Train. 2000 Apr-Jun; 35(2): 179–187.
PMCID: PMC1323415

Asthma Medications: Basic Pharmacology and Use in the Athlete

Abstract

Objective:

Asthma is a chronic disease that affects athletes at all levels of sport. Several categories of drugs, including relatively new agents, are available to treat the asthmatic patient. By understanding the appropriate uses and effects of these drugs, the athletic trainer can assist the asthmatic athlete in improving therapeutic outcomes from the asthma therapy. The appropriate use of these medications includes not only the use of the appropriate drug(s), but also appropriate technique for administration, compliance with the prescribed dosing intervals, and sufficient care to avoid side effects.

Data Sources:

I searched MEDLINE and CINAHL from 1982 to 1999 and International Pharmaceutical Abstracts from 1990 to 1999. Terms searched were “asthma,” “athlete,”“athletic,” “exercise-induced,” “exercise,” “performance,” “therapy,” and “treatment.”

Data Synthesis:

Bronchodilators include β2 agonists, anticholinergics, and methylxanthines. Of these, the β2 agonists used by inhalation are the drugs of choice to treat an acute asthma attack or to prevent an anticipated attack (such as before exercise). Anti-inflammatory agents include corticosteroids mast cell-stabilizing agents, and antileukotrienes. Corticosteroids by inhalation are the drugs of choice for long-term treatment to curb the inflammatory process in the lung. Each of these drug categories has a unique mechanism of action. The athletic trainer who understands the appropriate use of these medications can help the athlete to obtain optimal results from drug therapy. Encouraging the athlete to comply with appropriate therapy, monitoring the effectiveness of the therapy, and recognizing the stimuli that initiate asthmatic attacks can improve the patient's therapeutic outcomes.

Conclusions/Recommendations:

The athletic trainer has an opportunity to play a key role in ensuring that the asthmatic athlete achieves the desired outcomes from treatment. The athletic trainer can help to minimize the effect of asthma on athletic performance by ensuring that the athlete uses inhaler devices properly, is compliant with the prescribed drug therapy, monitors pulmonary function appropriately, uses medications properly before exercise, and is aware of the factors that initiate asthma symptoms.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hopman WM, Owen JG, Gagne E. Assessment of the effect of asthma education on outcomes. Manag Care Interface. 1999 May;12(5):89–93. [PubMed]
  • Boulet LP, Chapman KR, Green LW, FitzGerald JM. Asthma education. Chest. 1994 Oct;106(4 Suppl):184S–196S. [PubMed]
  • Houglum JE. Pharmacologic considerations in the treatment of injured athletes with nonsteroidal anti-inflammatory drugs. J Athl Train. 1998 Jul;33(3):259–263. [PMC free article] [PubMed]
  • Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993 Oct;148(4 Pt 2):S1–26. [PubMed]
  • Dempsey OJ, Coutie WJ, Wilson AM, Williams P, Lipworth BJ. Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax. 1999 Jul;54(7):614–617. [PMC free article] [PubMed]
  • Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax. 1996 Aug;51(8):835–840. [PMC free article] [PubMed]
  • Avent ML, Gal P, Ransom JL, Brown YL, Hansen CJ. Comparing the delivery of albuterol metered-dose inhaler via an adapter and spacer device in an in vitro infant ventilator lung model. Ann Pharmacother. 1999 Feb;33(2):141–143. [PubMed]
  • Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr. 1999 Jul;135(1):22–27. [PubMed]
  • Wildhaber JH, Dore ND, Wilson JM, Devadason SG, LeSouëf PN. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr. 1999 Jul;135(1):28–33. [PubMed]
  • McFadden ER, Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med. 1994 May 12;330(19):1362–1367. [PubMed]
  • Morton AR, Fitch KD. Asthmatic drugs and competitive sport. An update. Sports Med. 1992 Oct;14(4):228–242. [PubMed]
  • Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996 Sep 19;335(12):841–847. [PubMed]
  • Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER., Jr Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998 Jul 16;339(3):141–146. [PubMed]
  • Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S69–S76. [PubMed]
  • Handley DA, Anderson AJ, Koester J, Snider ME. New millennium bronchodilators for asthma: single-isomer beta agonists. Curr Opin Pulm Med. 2000 Jan;6(1):43–49. [PubMed]
  • Smith BW, LaBotz M. Pharmacologic treatment of exercise-induced asthma. Clin Sports Med. 1998 Apr;17(2):343–363. [PubMed]
  • Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997 Mar 19;277(11):887–891. [PubMed]
  • Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med. 1999 Jul;160(1):157–161. [PubMed]
  • McFadden ER, Casale TB, Edwards TB, Kemp JP, Metzger WJ, Nelson HS, Storms WW, Neidl MJ. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J Allergy Clin Immunol. 1999 Jul;104(1):46–52. [PubMed]
  • O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet. 1993 Feb 6;341(8841):324–327. [PubMed]
  • Dahlén B, Margolskee DJ, Zetterström O, Dahlén SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993 Dec;48(12):1205–1210. [PMC free article] [PubMed]
  • Kinoshita M, Shiraishi T, Koga T, Ayabe M, Rikimaru T, Oizumi K. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):534–535. [PubMed]
  • Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet. 1999 Feb 27;353(9154):725–726. [PubMed]
  • Katz RS, Papernik M. Zafirlukast and Churg-Strauss syndrome. JAMA. 1998 Jun 24;279(24):1949–1950. [PubMed]
  • D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ. 1999 Feb 20;318(7182):475–476. [PMC free article] [PubMed]
  • Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998 Apr 15;279(15):1181–1186. [PubMed]
  • Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun;22(2):168–170. [PubMed]
  • Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1999 Jul;160(1):291–296. [PubMed]
  • Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999 Jul;104(1):5–13. [PubMed]
  • Small E, Bar-Or O. The young athlete with chronic disease. Clin Sports Med. 1995 Jul;14(3):709–726. [PubMed]
  • Emtner M, Finne M, Stålenheim G. A 3-year follow-up of asthmatic patients participating in a 10-week rehabilitation program with emphasis on physical training. Arch Phys Med Rehabil. 1998 May;79(5):539–544. [PubMed]
  • Emtner M, Finne M, Stålenheim G. High-intensity physical training in adults with asthma. A comparison between training on land and in water. Scand J Rehabil Med. 1998 Dec;30(4):201–209. [PubMed]
  • Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol. 1995 Oct;96(4):480–485. [PubMed]
  • Hough DO, Dec KL. Exercise-induced asthma and anaphylaxis. Sports Med. 1994 Sep;18(3):162–172. [PubMed]
  • Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998 Jul 16;339(3):147–152. [PubMed]
  • Weiler JM, Layton T, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J Allergy Clin Immunol. 1998 Nov;102(5):722–726. [PubMed]

Articles from Journal of Athletic Training are provided here courtesy of National Athletic Trainers Association